



(51) International Patent Classification:

A61K 47/68 (2017.01) *C07K 5/06* (2006.01)
A61P 35/00 (2006.01) *C07K 5/08* (2006.01)
C07D 491/22 (2006.01) *C07K 5/10* (2006.01)

(21) International Application Number:

PCT/EP2020/057984

(22) International Filing Date:

23 March 2020 (23.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/826393 29 March 2019 (29.03.2019) US
 62/964177 22 January 2020 (22.01.2020) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **HOWARD, Philip, Wilson**; c/o MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **DICKINSON, Niall**; c/o MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **CAILLEAU, Thais**; c/o MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

ta Park, Cambridge Cambridgeshire CB21 6GH (GB). **MASTERSON, Luke**; c/o MedImmune Limited Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **GOUNDRY, William**; c/o AstraZeneca 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AA (GB).

(74) Agent: **WINSHIP, Emma, Victoria, Bristowe, Wallace** et al.; AstraZeneca Intellectual Property Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: COMPOUNDS AND CONJUGATES THEREOF





Fig. 1



(57) Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*